News
Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...
AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part ...
AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...
US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...
AbbVie has shared promising top-line results from a late-stage study of its JAK inhibitor Rinvoq (upadacitinib) in severe ...
AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...
AbbVie, a global leader in life sciences, announced Tuesday the company’s is investing $195 million to expand its North ...
17h
WQRF Rockford on MSNIllinois secures AbbVie’s $195 million investment for North Chicago facility
AbbVie, the maker of Botox, Humira, and Rinvoq, will invest $195 million to expand its North Chicago manufacturing facility, ...
StockStory.org on MSN10h
5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call
AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and ...
21h
TipRanks on MSNAbbVie announces $195M investment to expand API manufacturing in U.S.
AbbVie (ABBV) announced a $195M investment in its North Chicago, Illinois manufacturing plant to expand domestic active ...
As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...
AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results